Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

108.18 +2.79 (+2.65%)
Streaming Delayed Price Updated: 3:48 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,563,033
Open 105.97
Bid (Size) 108.12 (100)
Ask (Size) 108.22 (200)
Prev. Close 105.39
Today's Range 104.08 - 109.69
52wk Range 66.74 - 112.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Why Incyte (INCY) Stock Is Up Today
What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.8% in the morning session after several analyst firms raised the... 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
+6.7%
+6.7%
1 Month
+7.8%
+7.8%
3 Month
+14.3%
+14.3%
6 Month
+13.7%
+13.7%
1 Year
+54.4%
+54.4%

More News

Read More
News headline image
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
Via StockStory
Topics Credit Cards Stocks
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Via The Motley Fool
Topics Regulatory Compliance
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗
Via Chartmill
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
From Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
From Incyte
Via Business Wire
News headline image
3 Profitable Stocks for Long-Term Investors
Via StockStory
News headline image
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Incyte
Via Business Wire
News headline image
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗
Via MarketBeat
News headline image
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
From Genesis Molecular AI and Incyte
Via Business Wire
News headline image
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
From Incyte and Edison Scientific
Via Business Wire
News headline image
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build ↗
Via MarketBeat
News headline image
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
From Incyte
Via Business Wire
News headline image
2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore
Via StockStory
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance
Via StockStory
News headline image
Incyte (INCY) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 108.18
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 06/11/26 03:48 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 24.06B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 24B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.